Sequencing therapy in metastatic renal cell cancer.

abstract：:Previously untreated patients with stages I to IV, N0-3, M0 unresectable non-small cell lung cancer were randomized to arm I (conventional radiotherapy [RT], 60 Gy in 30 fractions over 6 weeks), arm II (accelerated RT, 60 Gy in 30 fractions over 3 weeks), arm III (conventional RT, as in arm I, plus carboplatin 70 mg/m...

journal_title：Seminars in oncology

authors： Bishop JF,Ball D,Crennan E,Ryan G,Davis S,Toner G,O'Brien P,Olver I

更新日期：1994-06-01 00:00:00

abstract：:A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may al...

journal_title：Seminars in oncology

authors： Ettinger DS

更新日期：2005-04-01 00:00:00

abstract：:Carcinoma of the bladder is the most prevalent cancer in Egypt and in most African countries. At the National Cancer Institute (NCI), Cairo, it constitutes 30.3% of all cancers. The median age at diagnosis is 46 years, with a male preponderance of 5:1. Whether in Egypt or other African countries such as Sudan, Kenya, ...

journal_title：Seminars in oncology

authors： el-Mawla NG,el-Bolkainy MN,Khaled HM

更新日期：2001-04-01 00:00:00

abstract：:Evidence published during several decades has shown that there is a group of epithelial ovarian tumors having histological and biological features between those of clearly benign and frankly malignant tumors. In 1963, FIGO accepted an intermediate group of ovarian carcinomas of low malignant potential. In 1973, WHO ad...

journal_title：Seminars in oncology

authors： Tropé C,Kaern J

更新日期：1998-06-01 00:00:00

abstract：:Bendamustine has clinical potential in the treatment of low-grade non-Hodgkin's lymphoma (NHL). As a single agent, bendamustine has been used in two studies in patients with relapsed or refractory low-grade NHL. When bendamustine 120 mg/m(2) was given on days 1 and 2, the overall response rate was 73% with complete re...

journal_title：Seminars in oncology

authors： Rummel MJ,Mitrou PS,Hoelzer D

更新日期：2002-08-01 00:00:00

abstract：:Many novel antifolate compounds with unique pharmacologic properties are currently in clinical development. These newer antifolates differ from methotrexate, the most widely used and studied drug in this class, in terms of their lipid solubility and cellular transport affinity, their level of polyglutamation, and thei...

journal_title：Seminars in oncology

authors： Takimoto CH

更新日期：1997-10-01 00:00:00

abstract：:One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activates multiple signaling cascades that promote carcinogenesis and immune evasion. Therefore, these molecules have been extensively targeted in cancer immunotherapy. Beyond EGFR signaling cascade inhibition, some of these agen...

journal_title：Seminars in oncology

authors： Mazorra Z,Chao L,Lavastida A,Sanchez B,Ramos M,Iznaga N,Crombet T

更新日期：2018-01-01 00:00:00

abstract：:This paper is designed to provide an introduction to music therapy in the continuum of cancer care. The value and use of music therapy during diagnosis and treatment, palliation, hospice, actively dying, and bereavement have been well documented. The music therapy process will be identified, research will be shared, a...

journal_title：Seminars in oncology

authors： Gallagher LM

更新日期：2011-06-01 00:00:00

abstract：:Several new antimetabolites have been evaluated in clinical trials in recent years. Those with the most promising activity include the structurally related purine analogs fludarabine, 2-chlorodeoxyadenosine, and 2'-deoxycoformycin. These compounds have shown impressive activity against a broad spectrum of indolent lym...

journal_title：Seminars in oncology

authors： Cheson BD

更新日期：1992-12-01 00:00:00

abstract：:Sentinel nodes (SNs) are the first set of nodes to receive drainage and cancer cells from a primary tumor. While there may be a single SN, frequently there are one to three or more SNs. The development of sentinel node surgery over the last decade has led to dramatic changes in the surgical approach to regional nodes ...

journal_title：Seminars in oncology

authors： Krag DN,Weaver DL

更新日期：2002-06-01 00:00:00

abstract：:The current oncology practice of treating cancer with aggressive doses of radiation and chemotherapy is potentially disastrous, as response and side effects vary depending on several factors including pharmacogenetics. This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and ...

journal_title：Seminars in oncology

authors： Wu X,Lu C,Chiang SS,Ajani JA

更新日期：2005-12-01 00:00:00

abstract：:Ifosfamide was developed by investigators at Asta-Werke in Germany. Its chemical structure differs from that of cyclophosphamide by the transposition of one of the side chain chloroethyl groups to the ring nitrogen. In several preclinical models, ifosfamide had greater activity than cyclophosphamide. It produced less ...

journal_title：Seminars in oncology

authors： Loehrer PJ Sr

更新日期：1992-12-01 00:00:00

abstract：:Recent improvements in the management of people living with human immunodeficiency virus (HIV) disease in the United States have led to remarkable reductions in HIV-related morbidity and mortality. The Centers for Disease Control and Prevention recently reported substantial reductions in acquired immunodeficiency synd...

journal_title：Seminars in oncology

authors： Sherer R

更新日期：1998-04-01 00:00:00

abstract：:Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's...

journal_title：Seminars in oncology

authors： Hricak H,Schöder H,Pucar D,Lis E,Eberhardt SC,Onyebuchi CN,Scher HI

更新日期：2003-10-01 00:00:00

abstract：:Monoclonal antibodies directed at the lymphoid antigens have become established treatments for hematological malignancies either alone or in combination with chemotherapy. However, their incorporation in the transplant setting remains investigational. This review focuses on the currently available data for in vitro an...

journal_title：Seminars in oncology

authors： Wasil T,Rai KR,Mehrotra B

更新日期：2004-02-01 00:00:00

abstract：:Many small cell carcinomas share morphological and physiological characteristics with normal and neoplastic cells of Pearse's APUD series, including pulmonary APUD cells and pulmonary carcinoid tumors. There is very likely more than one type of APUD cell in the lung, and conclusions that small cell carcinomas and carc...

journal_title：Seminars in oncology

authors： Tischler AS

更新日期：1978-09-01 00:00:00

abstract：:Drug resistance is one of the most important problems in the treatment of cancer. Patients become resistant not only to the drugs used initially, but also those to which they have not yet been exposed. A number of factors influence the therapeutic outcome of patients with breast cancer, foremost of which is the tumor ...

journal_title：Seminars in oncology

authors： Dalton WS

更新日期：1990-08-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the pla...

journal_title：Seminars in oncology

authors： Kearns CM,Gianni L,Egorin MJ

更新日期：1995-06-01 00:00:00

abstract：:The ability to predict the biological behavior of breast tumors can allow selection of the optimum treatment and follow-up strategies. Conventionally, tumor size, lymph node metastases, and histopathologic features have been used to determine the risk of systemic relapse. The discovery of a number of specific genetic ...

journal_title：Seminars in oncology

authors： Dhingra K,Hortobagyi GN

更新日期：1996-08-01 00:00:00

abstract：:The American Joint Committee on Cancer (AJCC) recently launched a new staging system for cutaneous melanoma that was based on clinical experience with a large number of patients treated in major centers worldwide. As this system includes various histopathologic parameters of the primary melanoma and of melanoma metast...

journal_title：Seminars in oncology

authors： Ruiter DJ,Spatz A,van den Oord JJ,Cook MG,Pathology Committee of the European Organization Research and Treatment of Cancer (EORTC) Melanoma Group.

更新日期：2002-08-01 00:00:00

abstract：:Since its introduction, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antitumor activity in epidermoid carcinomas and adenocarcinomas originating in the esophagus. Paclitaxel is the most active single agent available to treat metastatic esophageal cancer. Combinations of ...

journal_title：Seminars in oncology

authors： Weiner LM

更新日期：1999-02-01 00:00:00

abstract：:Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria toxin to cells that overexpress the IL-2 receptor. The human IL-2 receptor exists in three isoforms: low (CD25), intermediate (CD122/CD132), and high (CD25/CD122/CD132) affinity. The high-a...

journal_title：Seminars in oncology

authors： Foss F

更新日期：2006-02-01 00:00:00

abstract：:To evaluate the activity of thalidomide in Waldenstrom's macroglobulinemia (WM), 20 patients were treated on a dose schedule that escalated from 200 mg/d to 600 mg/d. On an intention-to-treat basis, five (25%) patients achieved a partial response, which was noted within 3 months of treatment. Adverse effects were comm...

journal_title：Seminars in oncology

authors： Dimopoulos MA,Tsatalas C,Zomas A,Hamilos G,Panayiotidis P,Margaritis D,Matsouka C,Economopoulos T,Anagnostopoulos N

更新日期：2003-04-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is the most common adult leukemia but is currently incurable by conventional therapeutic interventions. Rituximab has proven efficacy and tolerability in non-Hodgkin's lymphoma, achieving response rates of 73% and 48% in previously untreated or relapsed/refractory indolent non-Hodgki...

journal_title：Seminars in oncology

authors： Montserrat E

更新日期：2003-02-01 00:00:00

abstract：:Three hematopoietic growth factors, erythropoietin, GM-CSF, and G-CSF, have all been evaluated in the context of HIV infection. Recombinant human Epo is currently licensed for therapy of anemia related to zidovudine and is well tolerated in this patient population. Although myelosuppression can clearly be overcome usi...

journal_title：Seminars in oncology

authors： Groopman JE,Feder D

更新日期：1992-08-01 00:00:00

abstract：:Most malignant melanomas in the ocular region arise in the uveal tract (iris, ciliary body, and choroid). Uveal melanoma generally has characteristic clinical features and the diagnosis can usually be made by an experienced ophthalmologist using slit lamp biomicroscopy or indirect ophthalmoscopy. Ancillary studies suc...

journal_title：Seminars in oncology

authors： Shields JA,Shields CL,De Potter P,Singh AD

更新日期：1996-12-01 00:00:00

abstract：:Stem cell transplantation has been successfully used to treat a wide variety of hematologic malignancies. New and exciting strategies being developed for use in conjunction with transplant will be useful in overcoming tumor resistance. It is now clear that a significant part of the antitumor effect of allogeneic stem ...

journal_title：Seminars in oncology

authors： Margolis J,Borrello I,Flinn IW

更新日期：2000-10-01 00:00:00

abstract：:Rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc, San Francisco, CA) is a genetically engineered monoclonal antibody for the treatment of non-Hodgkin's lymphoma. This chimeric mouse/human, immunoglobulin GI kappa anti-CD20 antibody mediates complement-dependent cell lysis and antibody-depend...

journal_title：Seminars in oncology

authors： Grillo-López AJ,White CA,Varns C,Shen D,Wei A,McClure A,Dallaire BK

更新日期：1999-10-01 00:00:00

abstract：:The outcome of chemotherapy for patients with stage IV melanoma is unsatisfactory, since durable responses are rarely achieved. More experimental treatments, such as vaccine approaches, antibody treatments, and gene therapy are being developed and are of high scientific interest; however, their efficacy in advanced me...

journal_title：Seminars in oncology

authors： Keilholz U,Gore ME

更新日期：2002-10-01 00:00:00

abstract：:Distant metastasis is the major cause for therapeutic failures in Clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease....

journal_title：Seminars in oncology

authors： Gilboa E

更新日期：1996-02-01 00:00:00